Showing results (1-10 of 21) with videos related to
Sort By:
Pageof 3
Clinical Medicine (London, England)|May 14, 2004
Seizures: assessment and management in the emergency unitPhilip E M Smith, Mark D CossburnSeizure|August 25, 2004
Levetiracetam as add-on therapy in generalised epilepsiesS Pradeep Kumar, Philip E M SmithJournal of the Royal Society of Medicine|July 2, 2004
Scoring posters at scientific meetings: first impressions countPhilip E M Smith, Geraint Fuller, Frank DunstanSeizure|November 3, 2004
The investigation of syncopeSavvas Hadjikoutis, Peter O'Callaghan, Philip E M SmithEpilepsia|July 12, 2008
In utero exposure to vigabatrin: no indication of visual field lossCharlotte Lawthom, Philip E M Smith, John M WildCNS Drugs|June 29, 2019
Objective Derivation of the Morphology and Staging of Visual Field Loss Associated with Long-Term Vigabatrin TherapyJohn M Wild, Philip E M Smith, Carlo KnuppThe British Journal of Ophthalmology|March 18, 2025
Machine-learning algorithms for the identification of visual field loss associated with the antiseizure medication vigabatrin-a proof of conceptJohn M Wild, Philip E M Smith, Carlo KnuppOphthalmology|January 27, 2009
Nasal retinal nerve fiber layer attenuation: a biomarker for vigabatrin toxicityCharlotte Lawthom, Philip E M Smith, John M WildSeizure|September 19, 2002
Sudden unexplained death in epilepsy (SUDEP) following previous seizure-related pulmonary oedema: case report and review of possible preventative treatmentRosemary A Swallow, Charles E M Hillier, Philip E M SmithCNS Drugs|January 15, 2019
The Topographical Relationship between Visual Field Loss and Peripapillary Retinal Nerve Fibre Layer Thinning Arising from Long-Term Exposure to VigabatrinJohn M Wild, Saleh Aljarudi, Philip E M Smith, et al.Pageof 3